Cell Therapy

Breaking

RAPS Euro Convergence 2026: Regulatory News - Day 1 Roundup Heart Failure 2026: Vutrisiran Data & European Pharma News Mifepristone Access Continues Under Supreme Court Hold as Planned Parenthood Responds to 5th Circuit Ruling

NewsApr 15, 2026

XellSmart Advances XS411 Parkinson's Cell Therapy to Phase II Trial After Positive Phase I Results

XellSmart launches multicenter Phase II trial for XS411, an iPSC-derived dopaminergic cell therapy for Parkinson's disease following encouraging Phase I data.

Dr. Yuki Tanaka

News by Topic

More News Topics

Press Releases

Analysis by Topic

More Analysis Topics

Whitepapers

Browse

By Region

Directory

By Region

For Suppliers

For Brands

Resources

Popular Topics

More Topics

Browse

About Us

Get in Touch

Quick Actions

Recent Searches

Popular Topics

Suggestions

XellSmart Advances XS411 Parkinson's Cell Therapy to Phase II Trial After Positive Phase I Results